MedinCell operates as a commercial-stage pharmaceutical company specializing in developing a portfolio of long-acting injectables spanning various therapeutic areas. The company’s proprietary technology, BEPO®, is designed to enhance patient compliance, improve treatment efficacy and accessibility, and reduce the environmental impact of pharmaceuticals. MedinCell engages in collaborations with leading pharmaceutical companies and foundations to advance Global Health by introducing new therapeutic options.